BACKGROUND: Accurate measurement of free thyroxine (FT 4 ) is important for diagnosing and managing thyroid disorders. Most laboratories measure FT 4 by direct analogue immunoassay methods. The validity of these methods have recently been questioned. The inverse log-linear relationship between FT 4 and thyroidstimulating hormone (TSH) is well described and provides a physiological rationale on which to base an evaluation of FT 4 assays.
Accurate measurement of thyroxine (T 4 ) 4 and thyroidstimulating hormone (TSH) is important for the management of thyroid disorders. In serum, the majority of thyroxine circulates bound to high-concentration, low-affinity proteins, mostly albumin (ALB) and transthyretin, and to a low-concentration, high-affinity binding protein, namely thyroxine-binding globulin (TBG). Only a small percentage of total thyroxine (TT 4 ) circulates free (1 ) . It is widely accepted that it is the free thyroxine (FT 4 ) that is biologically active and, therefore, of most interest to monitor in patients with thyroid disorders (2 ) .
From 1990 to 2004, the Nichols equilibrium dialysis (ED)/RIA method was regarded by endocrinologists and laboratorians alike as the state-of-the-art FT 4 procedure (3 ). In addition, previous studies demonstrated an excellent comparison between the Nichols ED/RIA and ultrafiltration followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (4, 5 ) . Today the gold standard for the measurement of FT 4 is considered to be ED or ultrafiltration (3, 6 ) , in which free analyte is first separated from that bound to serum proteins and then measured by a highly sensitive and specific T 4 assay. The imprecision of our ultrafiltration LC-MS/MS FT 4 method was previously reported to provide CVs rang-ing between 4.1% and 6.6% at concentrations between 0.66 and 2.62 ng/dL (8.5-33.8 pmol/L) (4 ). We found that the Nichols ED/RIA method, at the same concentrations, had CVs between 8% and 15%, which is similar to that found by Okabayashi et al. (7 ) . Ultrafiltration for routine everyday use also has the advantage of being less time consuming (30 -40 min vs at least 17-24 h for ED).
In practice, most clinical laboratories use direct (analog) immunoassays for the measurement of FT 4 (8 ) . There are multiple FT 4 immunoassay methods, but most are based on T 4 analog binding and displacement (9 ) and rely on the measurement of FT 4 in diluted serum without the preparation of protein free fractions. The validity of free thyroid hormone measurement by direct analog immunoassay is still debated and has many limitations (10 -12 ) . FT 4 results by immunoassay are poorly standardized (13, 14 ) and are affected by binding protein concentrations (15, 16 ) .
The inverse log-linear relationship between TSH and free thyroid hormone due to the negative feedback of these hormones on the pituitary is well described (17 ) and provides a physiological rationale for assessing the validity of FT 4 results in a clinical setting. A recent article suggests that the correlation of FT 4 with log TSH is poor on the Abbott Architect ci8200 IA platform, which uses the direct analog method for FT 4 measurement (18 ) .
The objective of this study was to investigate the validity of a direct analog Siemens immunoassay (IA) FT 4 
Methods

PARTICIPANTS
This study was a prospective study of samples received at the NIH Clinical Center (NIH-CC) from January 2010 to February 2010 for the measurement of FT 4 and TSH. Samples were selected for inclusion in the study to reflect a spectrum of normal, low, and high TSH results, as well as normal and low albumin results. In total, we included 109 samples for analysis. The study was approved by the Institutional Review Board of the NIH (Clinical Protocol number 93-CC-0094). .00 mIU/L), and TBG (reference interval 241-271 nmol/L) were measured on the same analyzer. We measured albumin (reference interval 34 -50 g/L) on the Dimension Vista (Siemens Healthcare Diagnostics) using a bromcresol purple dyebinding method. All immunoassays and protein measurements were performed at the NIH on the day of sample collection.
TEST METHODS
Methods performed at the NIH-CC
Methods performed at the Bioanalytical Core Laboratory, Georgetown University. MS-FT 4 measurements were performed as described (4, 19 -21 ) with minor modifications. Briefly, samples frozen at Ϫ80°C were thawed at room temperature, and 400 L serum was placed in a 30-kDa ultrafiltration device (Centrifree YM-30, Millipore) and centrifuged in an Eppendorf temperature-controlled centrifuge at 1113g for 30 min at 37°C. We then added 150 L ultrafiltrate to 450 L methanol containing deuterium-labeled L-thyroxine (T 4 -d 5 ) from IsoSciences used as internal standard (Ͼ96.2% pure), vortex-mix mixed, and centrifuged. We diluted 500 L of the supernatant with 600 L water and injected 600 L onto an Agilent SB C-18 (2.1 mm ϫ 50 mm, 3.5 m ID) chromatographic column. The HPLC system consisted of 3 Shimadzu LC-20AD pumps, a Shimadzu SIL-HTA autosampler, and a Shimadzu DGU-20A5 degasser. The procedure involved an online extraction step followed by activation of a built-in Valco switching valve and subsequent sample introduction into the mass spectrometer. After a 3-min wash with 20% (vol/vol) methanol in 0.01% acetic acid at a flow rate of 1.0 mL/min, the switching valve was activated and the analytes of interest were eluted from the column and introduced into the mass spectrometer with a water/methanol gradient (see Supplemental Table 1 , which accompanies the online version of this article at www.clinchem.org/content/ vol57/issue1).
We used an API-5000 tandem mass spectrometer (Applied Biosystems/MDS Sciex) equipped with TurboIonSpray source, operated in the negative ionization multiple reaction monitoring (MRM) mode. The MRM transitions monitored for FT 4 and T 4 -d 5 were 775.6/126.9 and 780.8/126.9, respectively. Compounddependent and instrument-dependent parameters of the mass spectrometer were collision gas 11, curtain gas 30, ion source gas1 15, ion source gas2 45, ionspray voltage 4200 V, probe temperature 670°C, and dwell time 250 ms. Declustering potential was Ϫ120 for FT 4 and Ϫ173 for T 4 -d 5 , and collision energy was Ϫ62 for FT 4 and Ϫ82 for T 4 -d 5 . Data were acquired and processed by Analyst 1.4.1 software package. L-Thyroxine for preparation of the calibration curve was obtained from Sigma. HPLC-grade methanol was from Fisher Scientific.
Differences between this and previously published methods included (a) ultrafiltration performed at 37°C [previous studies compared 25°C to 37°C, see Jonklaas et al. (20 ) 
STATISTICAL METHODS
We conducted statistical analysis using Analyze-it for Microsoft Excel. We used the Shapiro-Wilk test to test for normality, and we used correlation coefficient, Bland-Altman difference plots, and ordinary least square regression analysis to evaluate the methods.
Results
METHOD VALIDATION
Pearson correlation coefficient between the Agilent SB C-18 (2.1 mm ϫ 50 mm, 3.5 m ID) and Supelco LC-C-18-DB (3.0 mm ϫ 33 mm, 3.0 m ID) columns, with ultrafiltration performed at 37°C, was R ϭ 0.99 (95% CI, 0.98 -1.00), and the residual standard deviation (S y|x ) was 0.28 pmol/L. The slope was 0.86 (95% CI, 0.73-0.99), and the intercept was 0.68 pmol/L (95% CI, Ϫ2.36 to 3.72) calculated using weighted Deming regression analysis (n ϭ 15, range: 2.58 -387 pmol/L). Comparison of modified LC-MS/MS procedure with LC-MS/MS method at NMS Laboratories gave a slope of 0.95 (95% CI, 0.84 -1.06), an intercept of 2.67 (95% CI, 2.52-2.82) pmol/L, a R ϭ 0.99 (95% CI, 0.98 -1.00), and S y|x of 0.22 pmol/L (n ϭ 23, range 1.29 -343.14 pmol/L).
PARTICIPANTS AND TEST RESULTS
The study included 109 samples. The median TSH was 2.00 mIU/L and ranged between Ͻ0.02 mIU/L and 215 mIU/L. Twenty-five samples (23%) had TSH Ͻ0.04 mIU/L, 47 (43%) had TSH between 0.04 and 4.00 mIU/L, and 37 (34%) had TSH Ͼ4.00 mIU/L. The median ALB was 37 g/L and ranged between 14 and 45 g/L. Thirty-one samples (28%) had ALB Ͻ34 g/L. The mean TBG was 348 nmol/L (95% CI, 331-365) and ranged between 135 and 579 nmol/L.
METHOD COMPARISON
The Pearson correlation coefficient between IA-FT 4 and LC-MS/MS was 0.45 (95% CI 0.29 -0.59). BlandAltman difference plots between IA-MS and LC-MS/MS showed 95% limits of agreement to be between 32.61 and Ϫ42.43 pmol/L (see online Supplemental  Fig. 1) .
The inverse log-linear Pearson correlation between MS-FT 4 and log TSH, 0.84 (95% CI, 0.77-0.88), was significantly better (P Ͻ 0.0001) than between IA-FT 4 and log TSH, 0.45 (95% CI, 0.29 -0.59) (Fig. 1 ). For patients with TSH Ͻ0.40 mIU/L and TSH Ͼ4.00 mIU/L, the inverse log-linear Pearson correlation between MS-FT 4 and log TSH, 0.86 (95% CI, 0.77-0.91), (Fig. 2) .
The area under the curve (AUC), calculated using ROC curves, for the prediction of TSH Ͼ4.0 mIU/L was significantly better for MS-FT 4 
Discussion
In this study, the IA-FT 4 and MS-FT 4 methods yielded widely discrepant results; however, the MS-FT 4 method correlated significantly better with log TSH than IA-FT 4 . This suggests that this MS-FT 4 method more accurately reflects true FT 4 concentrations. One possible reason, demonstrated in this study, is that the IA-FT 4 concentration still remains dependent on both ALB and TBG concentration and therefore may not be a true reflection of free hormone concentration. The ultrafiltration device used in this MS-FT 4 method effectively removes proteins (22 ) and therefore removes protein-bound T 4 from the sample and replaces the dialysis step of the classic equilibrium dialysis method. The protein concentration in the ultrafiltrate is dependent on the filtration device used, temperature, centrifugal force, and time of centrifugation. The fact that no significant correlation exists in this study between FT 4 measured by ultrafiltration LC-MS/MS and albumin or TBG indicates that protein leakage does not play a role in our method.
The poor correlation between IA-FT 4 and log TSH, as well as the significant correlation between IA-FT 4 and ALB and TBG, highlights some of the limitations of current immunoassays for the measurement of FT 4 . It is important that clinicians be aware of these limitations to make informed clinical decisions. These limitations are important in conditions that affect binding protein concentration, such as acute illness, pregnancy (23 ) , and hereditary variants in the structure of TBG, ALB, or transthyretin (24 ) . It is doubtful that standardization of direct analog immunoassays, without addressing the dependence of FT 4 measured on binding protein concentration, will result in methods with acceptable performance, especially for diseased individuals. The increased availability of mass spectrometry in clinical laboratories coupled with a rapid ultrafiltration procedure described in this and 
Evaluating the Relationship between FT 4 and TSH
previous studies shows that it is possible for ultrafiltration LC-MS methods to be routinely adopted. Indeed, this is already the case at Children's National Medical Center, where such an approach has now been used routinely for Ͼ4 years.
Ultrafiltration was performed at 37°C instead of the previously published 25°C (19 ) . Switching from 25°C to 37°C increases FT 4 results by a factor of 1.5 (21 ) . As stated previously, the correlation of LC-MS/MS FT 4 with log TSH was excellent at both 25°C and 37°C (20, 25 ) .
A limitation of this study is that TSH was measured using an immunoassay. Although TSH measurement is generally considered reliable (8 ), TSH is not well defined, and no reference measurement procedure is available. TSH results differ among immunoassay manufacturers (26 ) . TSH is a glycoprotein that has various glycoforms in blood, and glycosylation patterns may differ with different thyroid disease states (27 ) . A further limitation is that no clinical information is available; the study may therefore include patients taking thyroid medication or with nonthyroidal illnesses, since these patients could not be excluded. These are, however, patients in which regular monitoring of TSH and FT 4 is routinely requested.
In conclusion, IA-FT 4 and MS-FT 4 yielded widely discrepant results. Ultrafiltration MS-FT 4 , however, correlated significantly better with log TSH. IA-FT 4 measurements still remained dependent on binding protein concentration. Clinicians need to be aware of current limitations of immunoassays for the measurement of FT 4 . The validity of current immunoassays for the measurement of FT 4 needs to be reexamined, and the more widespread adoption of ultrafiltration LC-MS/MS for the measurement of FT 4 may be warranted.
